Danaher Corp (NYSE:DHR) on Wednesday reported fourth-quarter 2025 sales of $6.84 billion, up 4.5% year-over-year, beating the consensus of $6.81 billion. Core revenue increased 2.5% year-over-year, in line with the expected low single digits.The life science giant reported adjusted earnings of $2.23 per share, beating the consensus of $2.15.Rainer Blair, President and CEO, on Wednesday stated, “We delivered a strong finish to the year with better-than-expected performance across our portfolio.  We were part ...

Halozyme Therapeutics (NasdaqGS:HALO) Update / briefing January 28, 2026 08:30 AM ET Company ParticipantsBrendan Smith - DirectorCorinne Johnson - Managing DirectorDavid Risinger - Senior Managing DirectorHelen Torley - President and CEOJason Butler - Managing DirectorMichael DiFiore - Managing DirectorMohit Bansal - Managing DirectorNicole LaBrosse - CFOConference Call ParticipantsMitchell Kapoor - Director and Senior Biotechnology AnalystOperatorGood morning. My name is Eric, and I will be your conference ...

Danaher (NYSE:DHR) Q4 2025 Earnings call January 28, 2026 08:00 AM ET Company ParticipantsDoug Schenkel - Managing Director of Life Science Tools and DiagnosticsJohn Bedford - VP of Investor RelationsMatt McGrew - EVP and CFOMichael Ryskin - Managing DirectorPatrick Donnelly - Managing DirectorRainer Blair - President and CEOScott Davis - Chairman and CEOTycho Peterson - Managing Director of Global EquitiesConference Call ParticipantsDan Brennan - Senior Equity Research Analyst and Managing DirectorDan Leon ...

Danaher (NYSE:DHR) Q4 2025 Earnings call January 28, 2026 08:00 AM ET Speaker2Good day, everyone. My name is Nikki, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's fourth quarter 2025 earnings results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press star, ...

Core Insights - The study led by the National Cancer Institute (NCI) demonstrated a median progression-free survival (PFS) of 9.6 months for the investigational drug PDS01ADC in patients with metastatic castration-resistant prostate cancer (mCRPC) [1][2] - The combination therapy showed a median PSA decline of 40%, with 6 out of 16 patients achieving more than a 50% decline [2] - PDS Biotech aims to advance PDS01ADC as a key component of its immuno-oncology pipeline, reinforcing its potential to enhance existing therapies across various solid tumor types [3] Company Overview - PDS Biotechnology Corporation is a late-stage immunotherapy company focused on transforming immune responses to cancer [4] - The company has initiated a pivotal clinical trial for its lead program targeting advanced HPV16-positive head and neck squamous cell cancers [4] - PDS Biotech's lead investigational therapy, PDS0101 (Versamune HPV), is being developed in combination with standard immune checkpoint inhibitors and PDS01ADC [4]

Core Insights - The FDA has granted Breakthrough Therapy Designation to NXC-201 for the treatment of relapsed/refractory AL Amyloidosis based on positive interim clinical results from the NEXICART-2 Phase 2 trial [1][3][4] Company Overview - Immix Biopharma, Inc. is recognized as the global leader in relapsed/refractory AL Amyloidosis, focusing on developing innovative therapies for this condition [9] - The company’s lead candidate, NXC-201, is a sterically-optimized BCMA-targeted CAR-T cell therapy designed to filter out non-specific activation and teach the immune system to eliminate toxic light chains [8][9] Clinical Development - NEXICART-2 is an ongoing multi-site U.S. Phase 2 clinical trial aimed at enrolling 40 patients to evaluate the efficacy of NXC-201 in relapsed/refractory AL Amyloidosis [5] - Final data from the NEXICART-2 trial is expected to be released this year, followed by a planned Biologics License Application (BLA) submission [1][4] Market Context - The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is projected to grow at a rate of 12% per year, reaching approximately 38,500 patients by 2026 [6] - The AL Amyloidosis market was valued at $3.6 billion in 2017 and is anticipated to reach $6 billion by 2025 [7]

Core Viewpoint - Pinnacle Food Group Limited has announced a collaboration with Bioboost Synbio Consulting Inc. to enhance research capabilities in biotechnology and precision fermentation, focusing on applications related to recombinant human lactoferrin [1][2][4] Group 1: Collaboration Details - The collaboration will involve research on recombinant human lactoferrin (rhLF), a protein with potential applications in health, nutrition, and functional food development [2] - The agreement includes technical consulting services, ecosystem scouting, and evaluation of research directions in agricultural technology, food technology, and biotechnology [2][3] Group 2: Strategic Importance - The collaboration aligns with the company's ongoing efforts in smart agriculture and advanced fermentation, aiming to improve technical understanding and research capabilities [3] - The CEO of Pinnacle Food Group Limited emphasized the importance of this collaboration in strengthening research capabilities and exploring innovative bioproducts [4]

IRVING, Texas, Jan. 28, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient- centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Nature's npj Breast Cancer journal titled, "Mechanisms of Resistance to Trastuzumab Deruxtecan in Breast Cancer Elucidated by Multiomic Molecular Profiling." Utilizing large-scale real-world clinico-genomic data and Caris's comprehensive multiomic profiling, Caris scientists uncovered clinically relevant mech ...

Core Insights - Genvor, Inc. has appointed Dr. George Stavrides as Executive Vice President, Business Development & Commercialization to enhance its strategic partnerships and market expansion efforts in sustainable agriculture [1][2] Company Overview - Genvor, Inc. is a biotechnology company focused on developing peptide-based solutions for crop protection and plant health, aiming to promote sustainable agriculture and reduce chemical inputs [4] Leadership Experience - Dr. Stavrides has over 15 years of experience in agrochemicals and biologicals, previously serving as Global Product Management Lead at Syngenta, where he managed over 500 biological product concepts and oversaw more than 50 product launches globally, resulting in a quadrupling of revenues over seven years [2][3] Strategic Focus - Dr. Stavrides will concentrate on expanding Genvor's commercial strategy, including strategic partnerships, licensing agreements, and collaborations with global agricultural companies [1][3] Industry Impact - The appointment of Dr. Stavrides is expected to accelerate Genvor's commercialization efforts and enhance its ability to address unmet grower needs through innovative biological technologies [3]

• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’ development of a single-molecule assay for measuring alpha-synuclein proteoforms is its latest application of Iterative Mapping method to uncover new biological insights• Weill Cornell Medicine-Qatar’s deep chemical biology and neurology expertise and field-leading protein standards and affinity reagents position the organizations to probe disease-associated proteof ...